Cargando…
Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy
Vascular endothelial growth factor A (VEGF-A) inhibition with pazopanib is an approved therapy for sarcomas, but likely results in compensatory pathways such as upregulation of hypoxia inducible factor 1α (HIF-1α). In addition, cancer stem-like cells can preferentially reside in hypoxic regions of t...
Autores principales: | Yoon, Changhwan, Chang, Kevin K., Lee, Jun Ho, Tap, William D., Hart, Charles P., Simon, M. Celeste, Yoon, Sam S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189991/ https://www.ncbi.nlm.nih.gov/pubmed/27374091 http://dx.doi.org/10.18632/oncotarget.10212 |
Ejemplares similares
-
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
por: Yoon, C, et al.
Publicado: (2015) -
Platelet-derived growth factor receptor-α and -β promote cancer stem cell phenotypes in sarcomas
por: Chang, Kevin K., et al.
Publicado: (2018) -
Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways
por: Valli, Alessandro, et al.
Publicado: (2014) -
Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1α in a FOXO3-dependent mechanism
por: Cho, Siyoung, et al.
Publicado: (2014) -
α-Ketoglutarate inhibits autophagy
por: Baracco, Elisa Elena, et al.
Publicado: (2019)